Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease
Open Access
- 11 February 2012
- journal article
- research article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 46 (2), 351-361
- https://doi.org/10.1016/j.nbd.2012.01.016
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01NS44169, HDSA35326, NIH R01NS045283, R01NS055158, U01NS063953, R01NS62856)
- Repligen Corporation
This publication has 42 references indexed in Scilit:
- Animal Models of Polyglutamine Diseases and Therapeutic ApproachesPublished by Elsevier BV ,2009
- Therapeutic application of histone deacetylase inhibitors for central nervous system disordersNature Reviews Drug Discovery, 2008
- Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s diseaseHuman Molecular Genetics, 2008
- Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disordersCurrent Opinion in Pharmacology, 2008
- Histone deacetylases: Focus on the nervous systemCellular and Molecular Life Sciences, 2007
- In Vitro Analysis of Huntingtin-Mediated Transcriptional Repression Reveals Multiple Transcription Factor TargetsCell, 2005
- The Sir2 Family of Protein DeacetylasesAnnual Review of Biochemistry, 2004
- Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase FamilyJournal of Biological Chemistry, 2002
- Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in DrosophilaNature, 2001
- Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular ToxicityScience, 2001